LXRX - Lexicon Pharma starts Phase 2 trial in post-herpetic neuralgia

Lexicon Pharmaceuticals (LXRX) has initiated the dosing of the Phase 2 trial for LX9211 for the treatment of post-herpetic neuralgia, a disease with limited treatment options.With the involvement of 74 patients, the randomized, double-blind, placebo-controlled, clinical study will evaluate the efficacy, safety, and pharmacokinetics of LX9211, in a disease suffered by people with shingles even months to years after the rash clears.LX9211 is an oral small-molecule inhibitor of adaptor-associated kinase 1 (AAK1) with Fast Track designation from the FDA for the development in diabetic peripheral neuropathic pain.Welcoming the fast-track designation, Seeking Alpha contributor, Stephen Simpson cites the lack of efficacy data in humans for LX9211 in a neutral thesis on the stock.

For further details see:

Lexicon Pharma starts Phase 2 trial in post-herpetic neuralgia